Morgan Stanley Upgrades Merck to Overweight, Raises Price Target to $179 on August 20
According to CNBC, Morgan Stanley analyst Terrence Flynn upgraded Merck (MRK) on August 20, raising the investment rating from Equal-weight to Overweight and lifting the price target from $116 to $179. Despite near-term pressure from Keytruda's patent expiration next year, Flynn forecasted that Merc
MRK0.06%
GateNews·08-21 00:23
